- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02836925
Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection
March 30, 2023 updated by: Fondazione Italiana Linfomi ONLUS
A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas
This is a non-randomized, a single arm, phase II multicentre study of sofosbuvir plus ledipasvir (genotype 1 and 4) or sofosbuvir plus velpatasvir (genotype 2 and 3) for patients with hepatitis C virus-associated indolent B-cell lymphomas (HCV-RNA positive).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years.
ORR and vital status will be also evaluated.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milano, Italy
- Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori
-
Milano, Italy
- Ospedale San Raffaele Ematologia
-
Padova, Italy
- U.O. Ematologia AO di Padova
-
Parma, Italy, 43126
- A.O. Universitaria Di Parma
-
Pavia, Italy, 27100
- Ematologia Policlinico San Matteo
-
Piacenza, Italy
- Ospedale Civile Piacenza
-
Roma, Italy
- Ematologia - Policlinico Umberto I Università Sapienza
-
Rozzano, Italy
- Dipartimento di Oncologia Medica ed Ematologia, Istituto Humanitas
-
Torino, Italy, 10126
- AOU Citta della Salute e della Scienza di Torino
-
Varese, Italy
- Ospedale di Circolo e Fondazione Macchi
-
-
BS
-
Brescia, BS, Italy, 25100
- A.O. Spedali Civili
-
-
Pordenone
-
Aviano, Pordenone, Italy, 33801
- Irccs Centro Di Riferimento Oncologico (CRO)
-
-
VI
-
Vicenza, VI, Italy, 36100
- Ospedale San Bortolo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age >18 years
- Indolent B cell lymphoma including: marginal zone lymphoma (nodal, extranodal, splenic and disseminated), lymphoplasmacytic lymphoma, small lymphocytic lymphoma, follicular lymphoma grade 1 and 2, CD5-negative B-cell lymphoma NOS
- HCV-RNA positivity
- Assessable HCV genotype
- No previous therapy for the lymphoma
- Measurable disease after diagnostic biopsy (longest axis ≥1.5 cm for nodal and ≥1 cm for extranodal lesions) and/or evaluable disease (quantifiable BM infiltrate and ≥5 x 109/l clonal B-cell in peripheral blood in case of exclusive BM/leukemic disease in CD5-negative Bcell lymphoma NOS)
- No need of immediate lymphoma treatment defined as absence of all the following criteria: systemic symptoms, bulky nodal or extranodal mass (>7 cm), symptomatic splenomegaly, progressive leukemic phase, serous effusions
- Performance status <2 according to ECOG scale
- Adequate hematological counts: ANC >1 x 109/L, hemoglobin >9 g/dl (transfusion independent), platelet count > 50 x 109/L (transfusion independent)
- No central nervous system (CNS) disease (meningeal and/or brain involvement by lymphoma)
- Adequate kidney function (creatinine clearance ≥ 45 ml/min)
- Cardiac ejection fraction ≥45% (echocardiography or MUGA scan)
- Normal lung function
- Non peripheral neuropathy or active neurological non neoplastic disease of CNS
- Non major surgical intervention prior 3 months to enrolment if not due to lymphoma and/or no other disease life-threatening that can compromise chemotherapy treatment
- Disease free of prior malignancies other than lymphoma for >3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
- Life expectancy > 6 months
- No psychiatric illness that precludes understanding concepts of the trial or signing informed consent
- Written informed consent
Women must be:
- postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months)
- surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
- completely abstinent (at the discretion of the investigator/per local regulations) (periodic abstinence from intercourse is not permitted) or
- if sexually active, be practicing a highly effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (eg: condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel, male partner sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study. They must also be prepared to continue birth control measures for at least 6 months after terminating treatment.
- Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening
- Men must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 1 month after receiving the last dose of study drug if not taking ribavirin of for 6 months after receiving the last dose of study drug if taking ribavirin.
Exclusion Criteria:
- Diagnosis of lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma grade 3, primary mediastinal B-cell lymphoma
- Previous anti-HCV treatment with sustained virological response
- Diagnosis of cirrhosis (histological or Stiffness >12 KpA)
- CNS disease (meningeal and/or brain involvement by lymphoma)
- History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
- Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug)
- Concomitant therapy with amiodarone
- Uncontrolled or severe cardiovascular disease including myocardial infarction within six months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina,
- Cardiac ejection fraction <45% (MUGA scan or echocardiography).
- Creatinine clearance <45 ml/min
- Presence of major neurological disorders
- HIV positivity, HBV positivity (HbsAg+ or HBV-DNA+) with the exception of HBcAb+, HbsAg-, HBsAb+/- patients with HBV-DNA negativity
- Ongoing systemic bacterial, fungal or viral infections at the time of initiation of study treatment (defined as requiring therapeutic dosing of an antimicrobial, antifungal or antiviral agent)
- Major surgical intervention prior 3 months to enrollment if not due to lymphoma and/or other
- Prior malignancies other than lymphoma in the last 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
- Life expectancy <6 months
- Any other coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
- If female, the patient is pregnant or breast-feeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir
The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years.
ORR and vital status will be also evaluated
|
Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg
Other Names:
Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg · 12 weeks of treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SVR12
Time Frame: 12 weeks from the end of the treatment
|
Sustained virologic response (SVR12) defined as undetectability of HCV-RNA 12 weeks after completion of antiviral therapy
|
12 weeks from the end of the treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: 12 weeks from the end of treatment
|
Overall response rate (ORR) of lymphoma: CR is defined by the complete disappearance of all detectable sites and symptoms; PR is defined as a more than 50% reduction.
Responses different from CR/PR are defined as stable disease (SD); progressive disease (PD) is considered an increase in size of more than 50% of previously documented disease or the appearance of new lesions.
Lymphoma response will be assessed 12 weeks after the end of antiviral treatment
|
12 weeks from the end of treatment
|
PFS
Time Frame: 36 months
|
Progression-free survival (PFS) defined as the time between enrolment and progression or relapse or death from any cause.
|
36 months
|
EFS
Time Frame: 36 months
|
Event-free survival (EFS) defined as time between enrolment and failure of treatment or death as a result of any cause
|
36 months
|
OS
Time Frame: 36 months
|
Overall survival (OS) defined as the time between enrolment and death from any cause
|
36 months
|
ORR for lymphoma
Time Frame: 12 weeks from the end of treatment
|
ORR for lymphoma according to Matutes criteria (Matutes et al, Leukemia 2008) only in patients with splenic-marginal zone lymphoma (SMZL)
|
12 weeks from the end of treatment
|
Rapid virological response
Time Frame: 4 weeks
|
rapid virologic response (RVR)
|
4 weeks
|
Extended rapid virological response
Time Frame: 4 weeks
|
extended RVR (eRVR)
|
4 weeks
|
Early virological response
Time Frame: 4 weeks
|
early virologic response (EVR)
|
4 weeks
|
Toxicity - Incidence of Adverse Events
Time Frame: 12 months
|
toxicity will be classified according to definitions of Common Terminology Criteria for Adverse Event version 4.03 (CTCAE).
It will be determined by the incidence of severe, life-threatening (CTCAE grade 3, 4 and 5) and/or serious adverse events
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Luca Arcaini, Fondazione IRCCS Policlinico San Matteo di Pavia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Actual)
February 1, 2020
Study Completion (Actual)
November 1, 2022
Study Registration Dates
First Submitted
February 25, 2016
First Submitted That Met QC Criteria
July 14, 2016
First Posted (Estimate)
July 19, 2016
Study Record Updates
Last Update Posted (Actual)
March 31, 2023
Last Update Submitted That Met QC Criteria
March 30, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Lymphoma
- Lymphoma, B-Cell
- Hepatitis
- Hepatitis A
- Hepatitis C
- Anti-Infective Agents
- Antiviral Agents
- Sofosbuvir
- Sofosbuvir-velpatasvir drug combination
- Velpatasvir
- Ledipasvir, sofosbuvir drug combination
- Ledipasvir
Other Study ID Numbers
- FIL_BArT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
Sohag UniversityRecruiting
Clinical Trials on Ledipasvir+Sofosbuvir
-
Assiut UniversityUnknown
-
Mansoura University Children HospitalUnknownHCV | Gaucher DiseaseEgypt
-
University Health Network, TorontoGilead SciencesCompletedHepatitis C, Chronic | Cirrhosis, DecompensatedCanada
-
Catherine ChappellGilead Sciences; University of NebraskaCompleted
-
Instituto de Investigación Marqués de ValdecillaCompleted
-
Third Affiliated Hospital, Sun Yat-Sen UniversityCompletedChronic Hepatitis C (Disorder)
-
Iran Hepatitis NetworkBaqiyatallah Research Center for Gastroenterology and Liver DiseasesUnknown
-
Ain Shams UniversityRecruitingHCV Infection | Beta Thalassemia MajorEgypt
-
Peter J. Ruane, M.D., Inc.CompletedTreatment of Hepatitis CUnited States
-
Ain Shams UniversityCairo UniversityCompletedHepatitis C, Chronic | Hematologic MalignancyEgypt